alexa Breakthroughs in Treatment of Chronic Hepatitis C - Time for an Obituary for Peginterferon/Ribavirin? | OMICS International | Abstract
ISSN: 2332-0877

Journal of Infectious Diseases & Therapy
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Breakthroughs in Treatment of Chronic Hepatitis C - Time for an Obituary for Peginterferon/Ribavirin?

Peter Ferenci*
Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Austria
Corresponding Author : Peter Ferenci
Department of Internal Medicine III
Division of Gastroenterology and Hepatology
Medical University of Vienna, Austria
Tel: +43-1-40400-4741
Fax: +43-1-40400-4735
E-mail: [email protected]
Received January 28, 2014; Accepted February 21, 2014; Published February 25, 2014
Citation: Ferenci P (2014) Breakthroughs in Treatment of Chronic Hepatitis C - Time for an Obituary for Peginterferon/Ribavirin? J Infect Dis Ther 2:130. doi: 10.4172/2332-0877.1000130
Copyright: © 2014 Ferenci P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Abstract

Within 2 years after licensing peginterferon/ribavirin and first generation protease inhibitors (telaprevir, boceprevir) for treatment of chronic hepatitis C the speed of development of new treatments has substantially increased. Combinations of various direct acting antivirals (DAA) like protease inhibitors (simeprevir, faldaprevir, ABT-450), HCV NS5A inhibitors (ie. daclatasvir, ledipasvir, ABT-267) and HCV RNA polymerase inhibitors (sofosbuvir, ABT-333) are highly effective and can cure hepatitis C without major side effects within 12 weeks. Once these combinations are approved by FDA and EMA they are likely to provide an interferon/ribavirin free treatment.

Recommended Conferences
Share This Page
Top